CN Mobile Logo

Search form


HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

Response to the HER2-targeted therapies lapatinib and trastuzumab are correlated with pathway-level genetic alterations, but not specific gene mutations.

Breast cancer tumors that are HER2-negative can spontaneously flip, with populations of circulating HER2-positive cells, suggesting treatment strategy.

Using updated FISH guidelines yields more women with breast cancer who may be eligible for HER2-directed therapy.

Results of the I-SPY 2 TRIAL found that the neoadjuvant combination of T-DM1 plus pertuzumab resulted in a greater benefit to HER2-positive breast cancer patients compared with paclitaxel plus trastuzumab.

Combining trastuzumab emtansine with docetaxel both with and without pertuzumab yielded promising efficacy in a phase Ib/IIa study of patients with HER2-positive locally advanced or metastatic breast cancer.

A quarter of women with HER2-positive breast cancer treated with a combination of lapatinib plus trastuzumab prior to surgery had significant tumor shrinkage within 11 days.

This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.


Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.